Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREOPANC-3: Perioperative vs Adjuvant FOLFIRINOX for Resectable Pancreatic Cancer
NCT04927780Phase 3Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Sep 2021
- Primary completion
- Jan 2027
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 2
01
Overview
A Phase 3 trial of oxaliplatin, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, folinic acid, fluorouracil in pancreatic ductal adenocarcinoma (PDAC), sponsored by Erasmus MC. Started Sep 2021; status: active, not recruiting.
02
Drugs
oxaliplatinirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabfolinic acidfluorouracil
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04927780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04927780.